Innovent Biologics, Inc.

IVBXF · OTC
Analyze with AI
6/30/2025
12/31/2024
6/30/2024
12/31/2023
Operating Activities
Net Income$834$298-$393-$889
Dep. & Amort.$266$0$199$183
Deferred Tax$0$0$0$0
Stock-Based Comp.$342$259$298$347
Change in WC-$1,093$569-$119$828
Other Non-Cash-$36$377-$200$301
Operating Cash Flow$314$1,503-$216$771
Investing Activities
PP&E Inv.-$103$0-$700-$521
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$647-$612$146-$1,202
Investing Cash Flow$545-$612-$554-$1,724
Financing Activities
Debt Repay.$548$0-$330$0
Stock Issued$0$0$0$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$100-$346$69$2,343
Financing Cash Flow$648-$346-$261$2,343
Forex Effect-$10$14-$2$24
Net Chg. in Cash$3,770-$1,714-$516$707
Supplemental Information
Beg. Cash$0$1,714$0$1,332
End Cash$3,770$0-$516$707
Free Cash Flow$211$1,237-$915$249